Studies have shown that the expression of HIF-1α is more prominent in the early stages of cancer, during which tumorigenesis, cellular proliferation, and survival are major events, while HIF-2α-mediated cancer pathways are more active during the later stages, when metastasis and chemoresistance take place [25]. This evidence concerns the gene EPAS1 and cancer.